LAWRENCEVILLE, N.J., Sept. 30, 2021 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that management will present at the following investment conferences in October:
Live and archived webcasts of these presentations will be available here.
About Celsion Corporation
Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV2. The company’s product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. Celsion also has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection. For more information on Celsion, visit www.celsion.com.
CONTACTS:
Celsion Corporation
Jeffrey W. Church
Executive Vice President and CFO
609-482-2455
jchurch@celsion.com
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com
# # #
BRIDGEPORT, CT, June 27, 2025 (GLOBE NEWSWIRE) -- The two leading academic institutions have joined…
Two-day cannabis trade events will connect brands, dispensaries, and budtenders for networking, product showcases, and…
Orange County, California, June 27, 2025 (GLOBE NEWSWIRE) -- Sage Healthspan, a California-based digital health…
You Cannot Silence the SciencePALM BEACH, Fla., June 27, 2025 (GLOBE NEWSWIRE) -- In less…
BRIDGEPORT, CT, June 27, 2025 (GLOBE NEWSWIRE) -- The two leading academic institutions have joined…
Lyophilization Process Innovation, Food Preservation Demand, and Pharmaceutical Industry Expansion Drive 7.9% CAGR Growth Across…